$5.80
3.33% yesterday
Nasdaq, Apr 04, 10:00 pm CET
ISIN
US88032L2097
Symbol
TENX

Tenax Therapeutics, Inc. Stock price

$5.80
-0.24 3.97% 1M
+2.46 73.65% 6M
-0.39 6.30% YTD
+1.98 51.83% 1Y
-1,234.20 99.53% 3Y
-1,034.20 99.44% 5Y
-109,114.20 99.99% 10Y
Nasdaq, Closing price Fri, Apr 04 2025
-0.20 3.33%
ISIN
US88032L2097
Symbol
TENX
Sector

Key metrics

Market capitalization $23.03m
Enterprise Value $-71.82m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 4.85
P/B ratio (TTM) P/B ratio 0.22
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-19.49m
Free Cash Flow (TTM) Free Cash Flow $-14.81m
Cash position $94.85m
EPS (TTM) EPS $-5.31
Short interest 11.91%
Show more

Is Tenax Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Tenax Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Tenax Therapeutics, Inc. forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a Tenax Therapeutics, Inc. forecast:

Buy
100%

Financial data from Tenax Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 6.78 6.78
36% 36%
-
- Research and Development Expense 13 13
293% 293%
-
-19 -19
137% 137%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -19 -19
137% 137%
-
Net Profit -18 -18
128% 128%
-

In millions USD.

Don't miss a Thing! We will send you all news about Tenax Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Tenax Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
5 days ago
CHAPEL HILL, N.C., March 31, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that the Company will present at the 24th Annual Needham Virtual Healthcare Conference, which is taking place virtually from A...
Neutral
GlobeNewsWire
10 days ago
Successfully Completed Private Placements with Aggregate Gross Proceeds of Approximately $125 Million to Support Advancement of Two Registrational Studies for TNX-103 in PH-HFpEF and Fund Operations through 2027
Neutral
GlobeNewsWire
about one month ago
CHAPEL HILL, N.C., March 05, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (the “Company” or “Tenax Therapeutics”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that it has entered into a securities purchase agreement for a private placement financing with RTW Investments, which is expe...
More Tenax Therapeutics, Inc. News

Company Profile

Tenax Therapeutics, Inc. engages in the identification, development, and commercialization of novel therapeutic products for the critical care market. Its lead product candidate is Levosimendan, a calcium sensitizer activator for intravenous use in hospitalized patients with acutely decompensated heart failure. The company was founded on May 26, 1967 and is headquartered in Morrisville, NC.

Head office United States
CEO Christopher Giordano
Employees 6
Founded 1967
Website www.tenaxthera.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today